Compare iShares Self-Driving EV and Tech (IDRV) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Self-Driving EV and Tech vs Sanofi SA — how do they compare? iShares Self-Driving EV and Tech trades at $35.9, while Sanofi SA trades at $43.78 (market cap $104.83B). The key difference: Sanofi SA pays a 5.5% dividend while iShares Self-Driving EV and Tech pays none. Which is the better fit depends on your goals.
| IDRV | SNY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $52.34 |
52-Week Low | $32.13 | $41.33 |
Market Cap | — | $104.83B |
Enterprise Value | — | $121.32B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDRV trades at $35.67, down 1.22% with a bearish technical outlook as moving averages signal strong selling pressure. Key financial ratios are unavailable, limiting fundamental assessment. Recent news highlights global EV sales growth, particularly in Europe and China, though U.S. adoption lags. A dividend of $0.30 is scheduled for June 2026, providing income potential amid market volatility.
The stock faces headwinds from technical weakness and competitive EV market dynamics. Upside depends on broader EV adoption trends and company-specific execution, while risks include regulatory changes and economic pressures. Investors should weigh the bearish signals against long-term sector growth opportunities.
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
